

A Phase I Study of SNH-119014 in Healthy Volunteers

NCT07087262

Status	RECRUITING
Phase	Phase 1
Sponsor	ScinnoHub Pharmaceutical Co., Ltd.
Enrollment	96 participants

Key Eligibility Criteria

Inclusion (4)

- Healthy male or female subjects;
- years of age, inclusive;
- Male subjects with body weight ≥ 50 kg, female subjects with body weight ≥ 45 kg; BMI ≥ 18.5 and ≤ 28.0 kg/m².
- Must provide written informed consent.

Exclusion (25)

- History of or current clinically significant circulatory system, endocrine system, nervous system, digestive system, respiratory system, urinary system, ophthalmology, hematology, immunology, psychiatry disorder, as judged by the investigator
- Subjects who have undergone major surgery 6 months prior to screening or who plan to undergo surgery during the study period;
- Clinically significant abnormal physical examination, vital signs, chest X-ray, laboratory tests during the screening period as judged by the investigator;
- Subjects with QTcF > 450 ms, or with other ECG clinically significant abnormalities during the screening period as judged by the investigator;
- Subject has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), treponema pallidum antibody, or human immunodeficiency virus (HIV) antibody at screening;

... and 20 more (see full listing online)

Locations (1 total)

The Second Hospital of Anhui Medical University, Hefei, Anhui, China